Repair of the PARP inhibitor induced break requires HRR; ergo, cancer cells which are HR defective (e.g. harbouring an oncogenic BRCA1 or BRCA2 variant) accumulate DNA damage eventually leading to cell death and are thus sensitive to PARP inhibition5,8,9. The gene discussed is PARP1; the disease is cancer.